30493-40-4

Usage

Type of compound

Heterocyclic compound

Structure

Contains a pyridine ring fused to an imidazole ring

Additional functional group

Ketone group attached to the pyridine ring

Presence of a substituent

Chloro substituent on the pyridine ring

Relevance in the field

Medicinal chemistry and pharmaceutical research

Potential

Possesses potential biological activity

Application

Utilized in the development of new drugs

Influence of chloro substituent

Adds to its reactivity and can influence its pharmacological properties

Versatility

Ketone functional group allows for further chemical modifications

Purpose of modifications

To enhance biological activity and selectivity

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 598-31-2 1-bromoacetone 

Downstream Products

• 719267-77-3 (2-{[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-yl]sulfinyl}-4-nitrophenyl)methanol 
• 751472-60-3 (2-{[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-yl]thio}-4-nitrophenyl)methanol 
• 917926-26-2 ethyl 2-{[4-(6-chloroimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-yl]thio}-4-nitrobenzoate 
• 372198-16-8 6-chloro-3-{2-[(2-methyl-5-nitrophenyl)thio]-1,3-thiazol-4-yl}imidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS

A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

Double (amino-sulfur generation of formic acid ) - 1,3-propane diester compound and its synthetic method, pharmaceutical composition and use thereof

The invention relates to a bis(aminodithioformate)-1,3-propane diester compound, and synthesis method thereof, a pharmaceutical composition containing the compound and a use, and especially relates to the use in preparing drugs for treating or preventing cancers. The compound is represented as the formula (I), wherein A is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, aryl alkyl or heteroaryl alkyl, or a substituted or unsubstituted heterocyclic ring formed together by the R1, the R2 and an N atom connected with the R1 and the R2.

A 2-amino-thiazole compounds (by machine translation)

The present invention relates to the technical field of pharmaceutical chemistry, particularly relates to a 2-amino thiazole compound or its pharmaceutically acceptable salts, its preparation method, and pharmaceutical compositions containing such compounds and its application in the preparation of antineoplastic. (by machine translation)

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors

3-{1-[(4-Fluorophenyl)sulfonyl]-1H-pyrazol-3-yl}-2-methylimidazo[1,2-a]pyridine, 2a, was discovered in our chemical library as a novel p110α inhibitor with an IC50 of 0.67 μM, through screening in a scintillation proximity assay. Optimization o